Skip to content
    Eli Lilly and Company logo

    Eli Lilly and Company

    Indianapolis, Indiana, United StatesFounded 1876
    www.lilly.comLinkedIn
    Biotech & Life SciencesHealthcare

    Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, founded in 1876. Through its corporate venture arm, Lilly Ventures, it invests in biotech and healthcare companies at early to expansion stages, providing portfolio companies access to laboratory infrastructure, scientific talent, and global clinical and commercial networks.

    61% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $74.3M (across 141 rounds with reported amounts).

    Find people at Eli Lilly and Company on Goldilocks AI

    Portfolio

    131

    Fund Size

    $300M

    Top Stage

    Series A

    Last 12 Mo

    20

    Team

    VE

    Vicky Erwin

    Managing Director of Public Investments and acting Deputy CIO of Pension and Benefits

    BR

    Brad Robling

    Lilly Ventures Global Head

    BR

    Brad Robling

    Lilly Ventures Global Head

    NN

    Nisha Nanda

    Lilly Ventures

    NN

    Nisha Nanda

    Lilly Ventures

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    171 investments
    CompanyRoundAmountDate
    BBigHatSeries C$75MSep 2026
    Superluminal Medicines logoSuperluminal MedicinesSeries B$60MSep 2026
    SSuperluminalUnknown$60MSep 2026
    NextCure logoNextCureSeries B$500MAug 2026
    RRemediumSeries A$10MAug 2026
    Remedium Bio logoRemedium BioSeries A$10MAug 2026
    Ratio logoRatioSeries C$70MJul 2026
    Flare Therapeutics logoFlare TherapeuticsSeries C—Jun 2026
    UUpDoc, Inc.Seed$18MJun 2026
    Lycia Therapeutics logoLycia TherapeuticsSeries D$75MJun 2026
    Terns Pharmaceuticals logoTerns PharmaceuticalsSeries C$87MMay 2026
    Incyclix Bio logoIncyclix BioSeries B$5MApr 2026
    CCrossbowSeries B—Mar 2026
    BreezeBio logoBreezeBioSeries B—Feb 2026
    TTRexBio, Inc.Series C$50MJan 2026
    Juvena Therapeutics logoJuvena TherapeuticsSeries B$33.5MJan 2026
    Recludix Pharma logoRecludix PharmaSeries B—Jan 2026
    Trex Bio logoTrex BioUnknown$50MJan 2026
    SonoThera logoSonoTheraSeries B$125MJan 2026
    SanegeneBio logoSanegeneBioSeries B$110MJan 2026
    Gate Bioscience logoGate BioscienceSeries B$65MNov 2025
    Trogenix logoTrogenixSeries A—Oct 2025
    Trogenix logoTrogenixSeries A$70MOct 2025
    DDualitasSeries A$65MSep 2025
    Dualitas Therapeutics logoDualitas TherapeuticsSeries A$65MSep 2025
    Page 1 of 7

    Top Co-Investors

    Alexandria Venture Investments32 shared
    Pfizer Ventures19 shared
    RA Capital Management17 shared
    Catalio Capital Management16 shared
    Polaris Partners15 shared
    OrbiMed14 shared
    Sofinnova Partners12 shared
    ARCH Venture Partners12 shared
    Forbion11 shared
    Novartis Venture Fund11 shared
    Insight Partners10 shared
    The Invus Group, LLC10 shared
    Bristol Myers Squibb9 shared
    Perceptive Advisors9 shared
    SV Health Investors9 shared
    Versant Ventures9 shared
    Gaingels8 shared
    Andreessen Horowitz7 shared
    T. Rowe Price7 shared
    Samsara BioCapital7 shared

    Last updated: 20 October 2026